Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice

268Citations
Citations of this article
149Readers
Mendeley users who have this article in their library.

Abstract

Parkinson's disease (PD) is characterized by a loss of ventral midbrain dopaminergic neurons, which can be modeled by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Inflammatory oxidants have emerged as key contributors to PD- and MPTP-related neurodegeneration. Here, we show that myeloperoxidase (MPO), a key oxidant-producing enzyme during inflammation, is upregulated in the ventral midbrain of human PD and MPTP mice. We also show that ventral midbrain dopaminergic neurons of mutant mice deficient in MPO are more resistant to MPTP-induced cytotoxicity than their wild-type littermates. Supporting the oxidative damaging role of MPO in this PD model are the demonstrations that MPO-specific biomarkers 3-chlorotyrosine and hypochlorous acid-modified proteins increase in the brains of MPTP-injected mice. This study demonstrates that MPO participates in the MPTP neurotoxic process and suggests that inhibitors of MPO may provide a protective benefit in PD. Copyright © 2005 Society for Neuroscience.

Cite

CITATION STYLE

APA

Choi, D. K., Pennathur, S., Perier, C., Tieu, K., Teismann, P., Wu, D. C., … Przedborski, S. (2005). Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson’s disease in mice. Journal of Neuroscience, 25(28), 6594–6600. https://doi.org/10.1523/JNEUROSCI.0970-05.2005

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free